Chronic and opportunistic infections in patients with immuno-inflammatory rheumatic diseases: screening and prevention issues (based on the materials of the EULAR recommendations)

At the present stage of development of rheumatology, much attention is paid to the problem of comorbid infections, which have a significant impact on mortality and mortality, especially in immuno-inflammatory rheumatic diseases (IIRD). The active introduction into clinical practice of innovative drugs, the action of which is aimed at specific components of the pathogenesis of IIRD, has led to an increase in the risk of developing infections of various nature and localization, including chronic and opportunistic (COI). This article analyzes the recommendations for screening and prevention of COI in adult patients with acute respiratory infections, proposed in November 2022 by experts of the European Alliance of Rheumatology Associations (EULAR). It is noted that these recommendations should be considered through the prism of national guidelines that take into account regional risk factors, features of the course, diagnosis, therapy and prevention of СOI. At the same time, it seems absolutely justified to periodically review screening and preventive procedures as new scientific data accumulate. Despite the importance of a multidisciplinary approach and the need for close cooperation with doctors of other specialties, the EULAR working group emphasizes the central role of a rheumatologist in the management of patients with HOI that occur against the background of IIRD and are associated with the received anti-rheumatic therapy.

[1]  J. Bijlsma,et al.  2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases , 2022, Annals of the Rheumatic Diseases.

[2]  J. Schoones,et al.  Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases , 2022, RMD Open.

[3]  G. Gridneva,et al.  Current issues in the management of patients with HIV infection and rheumatic diseases , 2021, Modern Rheumatology Journal.

[4]  Yoshiya Tanaka,et al.  Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry , 2021, Rheumatology.

[5]  J. Saegusa,et al.  Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids , 2021, Rheumatology International.

[6]  E. Lee,et al.  Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. , 2021, Clinical and experimental rheumatology.

[7]  Y. Tagashira,et al.  Reduction of Pneumocystis jirovecii pneumonia and bloodstream infections by trimethoprim–sulfamethoxazole prophylaxis in patients with rheumatic diseases , 2021, Scandinavian journal of rheumatology.

[8]  Chi-Ching Chang,et al.  Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study , 2021, Clinical Rheumatology.

[9]  Pengchong Li,et al.  Tuberculosis in patients with systemic lupus erythematosus–a 37‐year longitudinal survey‐based study , 2020, Journal of internal medicine.

[10]  A. Yamasaki,et al.  The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with rheumatic diseases , 2020, Modern rheumatology.

[11]  P. V. Casasempere,et al.  Pneumocystis jirovecii in immunocompromised patients with rheumatic diseases , 2020 .

[12]  T. Shim,et al.  Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis. , 2020, Joint bone spine.

[13]  M. Tong,et al.  Reactivation of Hepatitis B Virus: A Review of Clinical Guidelines , 2020, Clinical liver disease.

[14]  Yi‐Hsiang Huang,et al.  Low but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  Karina D. Torralba,et al.  Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California , 2020, Clinical Rheumatology.

[16]  Xinyi Wang,et al.  High risk of activation of latent tuberculosis infection in rheumatic disease patients , 2020, Infectious diseases.

[17]  T. Hanyu,et al.  Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital , 2019, Arthritis Research & Therapy.

[18]  E. Lee,et al.  Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole , 2019, Arthritis Research & Therapy.

[19]  V. Sundararajan,et al.  Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. , 2019, Clinics in liver disease.

[20]  H. Kikuchi,et al.  Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[21]  W. Grassi,et al.  Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis , 2019, Modern rheumatology.

[22]  A. Granel,et al.  Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy , 2018, European journal of rheumatology.

[23]  M. Okada,et al.  Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease? , 2018, Annals of the rheumatic diseases.

[24]  C. Mok Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. , 2018, Best practice & research. Clinical rheumatology.

[25]  T. Shim,et al.  The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea. , 2018, Respiratory medicine.

[26]  A. Geier,et al.  Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs—a single-center analysis of 2054 patients , 2018, Clinical Rheumatology.

[27]  N. Baykam,et al.  Clinical, radiological and prognostic features of influenza cases in the influenza epidemic during years 2016-2017. , 2018, Tuberkuloz ve toraks.

[28]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[29]  A. Ustianowski,et al.  Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy , 2018, Rheumatology.

[30]  M. Little,et al.  The complications of vasculitis and its treatment. , 2018, Best practice & research. Clinical rheumatology.

[31]  E. Lee,et al.  Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids , 2017, Annals of the rheumatic diseases.

[32]  J. Peacock,et al.  Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented? , 2017, Current Rheumatology Reports.

[33]  M. Tomita,et al.  Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial , 2017, Arthritis Research & Therapy.

[34]  J. Gómez-Reino,et al.  Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[35]  C. Bombardier,et al.  Increased risk of mycobacterial infections associated with anti-rheumatic medications , 2015, Thorax.

[36]  K. Reddy,et al.  American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. , 2015, Gastroenterology.

[37]  Jing-wen Ai,et al.  Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis , 2016, Clinical Rheumatology.

[38]  A. Lok,et al.  Management of patients with hepatitis B who require immunosuppressive therapy , 2014, Nature Reviews Gastroenterology &Hepatology.

[39]  D. Choquette,et al.  Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents , 2014, Clinical Rheumatology.

[40]  L. Punzi,et al.  Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients , 2014, Clinical Rheumatology.

[41]  C. Massone,et al.  Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. , 2011, Rheumatology.

[42]  L. Stamp,et al.  Is There a Role for Consensus Guidelines for P. jiroveci Pneumonia Prophylaxis in Immunosuppressed Patients with Rheumatic Diseases? , 2010, The Journal of Rheumatology.

[43]  C. Vogel,et al.  Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. , 2008, Rheumatology.

[44]  Mahboob Rahman,et al.  Glucocorticoid use, other associated factors, and the risk of tuberculosis. , 2006, Arthritis and rheumatism.

[45]  P. Geusens,et al.  High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors , 2003, Annals of the rheumatic diseases.

[46]  P. Thompson,et al.  Rifampicin reduces effectiveness and bioavailability of prednisolone. , 1983, British medical journal.